A Phase I, First-in-Human, Vehicle Controlled, Single Ascending Dose Trial Evaluating the Safety, Tolerability and Pharmacokinetics in Male Subjects With AD and in Healthy Male Subjects of Cutaneous Application of LEO 39652 Cream
Latest Information Update: 27 Jan 2015
At a glance
- Drugs LEO 39652 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; First in man
- Sponsors LEO Pharma
- 21 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Jan 2014 New trial record